Bottom line
RYCFX vs IBBQ: the short answer
RYCFX (Biotechnology Fund) and IBBQ (Invesco Nasdaq Biotechnology ETF) are both mutual funds.
But IBBQ is far broader, holding 261 positions to 74 for RYCFX, so beyond the top names it adds exposure RYCFX doesn't have.
IBBQ is cheaper at 0.19% vs 2.38% — a difference of $219 a year per $10,000 invested.
Over one year, RYCFX returned +28.4% vs −0.6% for IBBQ (reporting dates differ).
Updated Nov 19, 2026
RYCFX vs IBBQ side by side
| RYCFX | IBBQ | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | Guggenheim | Invesco |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 2.38% | 0.19% |
| Annual cost per $10k | $238 | $19 |
| 10-yr cost on $10k (prospectus) | $2,763 | $242 |
| Max front load | 0% | None |
| 12b-1 fee | 1% | — |
| 1-yr return | +28.4% | −0.6% |
| 5-yr return (annualized) | +3.0% | — |
| 10-yr return (annualized) | +4.8% | — |
| Best quarter | +28.0% | +12.0% |
| Worst quarter | −22.7% | −11.7% |
| Net assets (fund) | $136.8M | $67.4M |
| Number of holdings | 74 | 261 |
| Portfolio turnover | 75% | 17% |
| Returns as of | Dec 31, 2025 | Dec 31, 2024 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | RYCFX | IBBQ | Difference |
|---|---|---|---|
| 2024 | −1.7% | −0.6% | −1.1% |
| 2023 | +5.0% | +4.5% | +0.5% |
| 2022 | −13.9% | −10.2% | −3.7% |
Source: Fund prospectus bar charts
Holdings overlap
17 of RYCFX's top 25 holdings also appear in IBBQ's top 25.
| Holding | RYCFX | IBBQ |
|---|---|---|
| Amgen Inc | 5.05% | 7.10% |
| Gilead Sciences Inc | 4.49% | 7.39% |
| Vertex Pharmaceuticals Inc | 4.32% | 7.38% |
| Regeneron Pharmaceuticals Inc | 2.93% | 5.08% |
| Revolution Medicines Inc | 2.48% | 2.48% |
| Alnylam Pharmaceuticals Inc | 2.36% | 3.19% |
| Moderna Inc | 2.15% | 1.48% |
| Biogen Inc | 2.13% | 2.29% |
| Illumina Inc | 1.94% | 1.98% |
| Insmed Inc | 1.79% | 1.83% |
| United Therapeutics Corp | 1.72% | 1.94% |
| Guardant Health Inc | 1.72% | 1.35% |
| Incyte Corp | 1.62% | 1.53% |
| Viatris Inc | 1.55% | 1.49% |
| Neurocrine Biosciences Inc | 1.52% | 1.26% |
Source: SEC Form N-PORT
RYCFX top 10
- Abbvie Inc — 8.17%
- Amgen Inc — 5.05%
- Gilead Sciences Inc — 4.49%
- Vertex Pharmaceuticals Inc — 4.32%
- Regeneron Pharmaceuticals Inc — 2.93%
- Revolution Medicines Inc — 2.48%
- Alnylam Pharmaceuticals Inc — 2.36%
- Beone Medicines Ltd — 2.17%
- Moderna Inc — 2.15%
- Biogen Inc — 2.13%
IBBQ top 10
- Invesco Private Prime Fund — 14.20%
- Gilead Sciences, Inc. — 7.39%
- Vertex Pharmaceuticals Inc. — 7.38%
- Amgen Inc. — 7.10%
- Invesco Private Government Fund — 5.48%
- Regeneron Pharmaceuticals, Inc. — 5.08%
- Alnylam Pharmaceuticals, Inc. — 3.19%
- Revolution Medicines, Inc. — 2.48%
- Biogen Inc. — 2.29%
- Illumina, Inc. — 1.98%
FAQ
What is the difference between RYCFX and IBBQ?
Which is cheaper, RYCFX or IBBQ?
Should I own both RYCFX and IBBQ?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.